Results 41 to 50 of about 12,566,431 (163)

F9 Malmö, factor IX and deep vein thrombosis

Haematologica, 2009
Background We recently reported the association between the Malmö sequence variant in F9 (rs6048) and deep vein thrombosis.Design and Methods We aimed to study whether the association between F9 Malmö and deep vein thrombosis is explained by linkage ...
Irene D. Bezemer, Andre R. Arellano, Carmen H. Tong, Charles M. Rowland, Helen A. Ireland, Kenneth A. Bauer, Joseph Catanese, Pieter H. Reitsma, Carine J.M. Doggen, James J. Devlin, Frits R. Rosendaal, Lance A. Bare   +11 more
doaj   +1 more source

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Blood, 2012
Current factor IX (FIX) products display a half-life (t(1/2)) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients with hemophilia B. This open-label, dose-escalation trial in previously treated adult subjects
A. Shapiro, M. Ragni, L. Valentino, N. Key, N. Josephson, J. Powell, G. Cheng, A. Thompson, J. Goyal, K. Tubridy, R. Peters, J. Dumont, D. Euwart, Lian Li, B. Hallén, P. Gozzi, A. Bitonti, Haiyan Jiang, A. Luk, G. Pierce   +19 more
semanticscholar   +1 more source

Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials

Journal of Blood Medicine, 2023
Maria Elisa Mancuso,1,2 Daniel Eriksson,3 Aletta Falk,3 Zalmai Hakimi,3 Piotr Wojciechowski,4,5 Marlena Wdowiak,4 Robert Klamroth6,7 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 2Humanitas ...
Mancuso ME, Eriksson D, Falk A, Hakimi Z, Wojciechowski P, Wdowiak M, Klamroth R   +6 more
doaj  

Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.

Blood, 2012
In previous work we transferred a human factor IX-encoding adeno-associated viral vector (AAV) into skeletal muscle of men with severe hemophilia B.
G. Buchlis, G. Podsakoff, A. Radu, S. Hawk, A. Flake, F. Mingozzi, K. High   +6 more
semanticscholar   +1 more source

Purificación del factor IX recombinante expresado en leche de cerdas transgénicas Purification of recombinant factor IX expressed in milk of transgenic sows

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2006
Se purificó a partir de la leche de cerdas transgénicas, factor IX recombinante, y se obtuvieron rendimientos entre 1 a 2 g de esta proteína por litro, lo que resulta una nueva vía para la obtención de este producto con una alta eficiencia, ya que su ...
Armando Cádiz Lahens, Aniel Moya Torres, William Velander, Manuel Limonta Vidal, Lázaro Joo Sánchez, Alexandro Rodríguez Rojas, Laritza Solarana Tito, Alina Díaz Concepción, Patricia Caunedo Almagro, Dunia Castillo González, Delfina Almagro Vázquez   +10 more
doaj  

Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow

Haematologica, 2015
The importance of factor Xa generation in thrombus formation has not been studied extensively so far. Here, we used mice deficient in either factor VIII or factor IX to determine the role of platelet-stimulated tenase activity in the formation of ...
Frauke Swieringa, Marijke J. E. Kuijpers, Moniek M. E. Lamers, Paola E. J. van der Meijden, Johan W. M. Heemskerk   +4 more
doaj   +1 more source

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Blood, 2012
A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate hemophilia B treatment by less frequent FIX dosing.

semanticscholar   +1 more source

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.

Blood, 2012
Gene therapy may provide a cure for hemophilia and overcome the limitations of protein replacement therapy. Increasing the potency of gene transfer vectors may allow improvement of their therapeutic index, as lower doses can be administered to achieve ...
Alessio Cantore, N. Nair, P. Della Valle, Mario Di Matteo, J. Mátrai, F. Sanvito, C. Brombin, C. Di Serio, A. D’Angelo, M. Chuah, L. Naldini, T. VandenDriessche   +11 more
semanticscholar   +1 more source

Coagulation Factor IX for Hemophilia B Therapy


Acta Naturae, 2012
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy.
N. Orlova, S. Kovnir, I. Vorobiev, A. G. Gabibov   +3 more
semanticscholar   +1 more source

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in north eastern part of India

Journal of Family Medicine and Primary Care, 2019
Introduction: Deficiency of factor VIII (Hemophilia A), factor IX (Hemophilia B) and Von Willebrand's factor are the most frequent coagulation defects.
Sandip Kumar, Sachidanand Sinha, Anju Bharti, Lalit P Meena, Vineeta Gupta, Jyoti Shukla   +5 more
doaj   +1 more source